High-throughput detection of neutralizing antibodies to SARS-CoV-2 variants using flow cytometry

Xiaohan Zhang[1,2*], Yajie Wang[4*], Mansheng Li[2*], Haolong Li[3*] , Xiaomei Zhang[2], Xingming Xu[2], Di Hu[5], Te Liang[2], Yunping Zhu[2], Yongzhe Li[3#], Bingwei Wang[1#] and Xiaobo Yu[2#]

Affiliations

[1]College of Medicine and Integrated Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China.

[2]State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences-Beijing (PHOENIX Center), Beijing Institute of Lifeomics, Beijing, 102206, China.

[3]Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing 100730, China.

[4]Department of Clinical Laboratory, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.

[5]ProteomicsEra Medical Co., Ltd., Beijing, 102206, China

[*]These authors contributed equally to this work.

[#]Correspondence to yuxiaobo@mail.ncpsb.org (X.Y.), bingweiwang@njubw.edu.cn (B.W.) and yongzhelipumch@126.com (Y. L).

Abstract

Detecting neutralizing antibodies (NAbs) to SARS-CoV-2 variants is crucial for controlling the spread of COVID-19. In this work, we developed a high-throughput assay for the broad systematic examination of NAbs to eleven SARS-CoV variants of concern (VOCs), which include D614G, Alpha, Beta, Gamma, Delta, Kappa, and Omicron sub-lineages BA.1, BA.2, BA.3, BA.4, and BA.5. The assay is cost-effective, reliable, 35-fold more sensitive than Luminex technology, and can include the new variants during SARS-CoV-2 evolution. Importantly, our results highly correlated with a commercial IgG serological assay (R = 0.89) and cPass, a U.S. FDA-approved surrogate virus neutralization test (sVNT) assay (R = 0.93). With our high-throughput NAb platform, we constructed a comprehensive overview of the interactions between SARS-CoV-2 VOCs' Spike trimer proteins and ACE2 receptors, leading to the identification of a monoclonal Ab with broad neutralizing activity. Furthermore, when compared to the D614G variant, we found that the serum NAbs elicited by the third dose vaccine (administered after 28 days) demonstrated decreased inhibition to multiple SARS-CoV-2 variants, including Gamma (0.94×), Alpha (0.91×), Delta (0.91×), Beta (0.81×), Kappa (0.81×), BA.2 (0.44×), BA.1 (0.43×), BA.3 (0.41×), BA.5 (0.35×) and BA.4 (0.33×), in cohort of 56 vaccinated individuals. Altogether, our

proteomics platform proves to be an effective tool to detect broad NAbs

in the population and aid in the development of future COVID-19

vaccines and vaccination strategies.

Keywords

SARS-CoV-2, flow cytometry, neutralization, antibody, COVID-19

Introduction

The ongoing coronavirus 2019 (COVID-19) pandemic, caused by the

severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),

remains a public health concern worldwide. This is primarily attributed

to the continuous evolution of the virus and its persistent transmission

across global populations[1]. For instance, over ten SARS-CoV-2

variants of concern (VOCs) have appeared, and these VOCs have the

potential to reduce the immune response[2]. According to reports, 17.13%

(95%CI, 7.55–26.71%) of asymptomatic infected individuals may have

long-term health consequences [3], which may include symptoms such

as fatigue, brain fog, dizziness, gastrointestinal symptoms, as well as

others [4].

Neutralizing antibodies (NAbs) of SARS-CoV-2 are a subset of

antibodies that block viral entry by inhibiting the interaction between

the SARS-CoV-2's surface protein, Spike, and the host cell's receptor,

angiotensin-converting enzyme 2 (ACE2). Such NAbs can be

produced following COVID-19 vaccination or SARS-CoV-2 infection.

Identifying SAR-CoV-2 NAbs is critical for assessing vaccine efficacy,

evaluating individual and population immunity, monitoring variant

susceptibility, and information public health measures to control the

spread of COVID-19. However, traditional methods of NAb detection,

such those that use a live virus or a pseudovirus-based neutralization

assay, are slow, expensive, carry a potential risk of infection, and may

require specialized biosafety level 3 (BSL3) facilities [5-8].

As an alternative approach, enzyme-linked immunosorbent assay

(ELISA) can perform the *in vitro* neutralizing testing using purified

Spike, ACE2, or Spike's receptor-binding domain (RBD) that interacts

directly with ACE2 during viral entry. Several commercial ELISA-based

surrogate virus neutralization tests (sVNT) have been developed,

including TECO sVNT (TECO Medical) and cPASS sVNT (GenScript),

which have been approved by the United States' (U.S.) Food and Drug

Administration (FDA) or received Conformite Europeenne (CE)

marking for use in the European Union [9, 10]. Unfortunately,

ELISA-based methods only detect a single variant at a time, making

them a time-consuming option when multiple SARS-CoV-2 variants are

analyzed [6].

To address this concern, Fenwick *et al.* developed a multiplexed

in-vitro quantitative neutralization assay using Luminex technology in

2021. The assay enables the detection of NAbs targeting various Spike

mutations, including D614G, D614G plus M153T, N439K, S477N,

S477R, E484K, S459Y, N501T, N501Y, K417N, 60-70, P681H, Y453F,

and their combinations. The results obtained from this assay correlated

with pseudovirus neutralization (R^2=0.65) and live virus infection (R^2=

0.825) assays [7].

In a similar vein, Lynch et al. developed a multiplexed surrogate

virus neutralization test (plex-sVNT) for detecting NAbs to seven

SARS-CoV-2 variants, namely, wild type, Alpha, Beta, Gamma, Delta,

Kappa, and Epsilon. The results highly correlated (> 96%) with those

obtained from a plaque reduction neutralization test (PRNT)[8].

However, it should be noted that these technologies have

limitations as they require access to specific Luminex and Bio-Rad

instruments, thereby restricting their use to specific laboratories.

Moreover, some recent Omicron variants have not been accessible for

analysis using these methods to date[11].

In this work, we developed a high-throughput broad neutralizing

antibody (bNAb) assay that enables the systematic detection of NAbs

to eleven SARS-CoV-2 VOCs that is reliable, cost-effective, sensitive,

and used with a standard flow cytometer [12]. These variants include

D614G, Alpha, Beta, Gamma, Delta, Kappa, Omicron BA.1, Omicron

BA.2, Omicron BA.3, Omicron BA.4, and Omicron BA.5. We conducted

a comparative analysis of NAb detection using our SARS-CoV-2 bNAb

assay with commercial ELISA-based serology and U.S. FDA-approved

cPASS sVNT assays. Furthermore, we explored the applications of the

SARS-CoV-2 bNAb assay for screening therapeutic Abs, assessing

their neutralizing activity SARS-CoV-2. Finally, we analyzed the broad

responses of serological NAbs to SARS-CoV-2 VOCs in individuals

who received the third dose of either the inactivated vaccine

(Sinovac-CoronaVac) or the recombinant subunit vaccine (ZF2001) for

COVID-19.

Results

Schematic illustration of SARS-CoV bNAb assay

In the SARS-COV-2 bNAb assay, illustrated schematically in Figure 1A,

the trimerized Spike protein of six non-Omicron variants (D614G, Alpha,

Beta, Kappa, Gamma, Delta) and five Omicron variants (BA.1, BA.2,

BA.3, BA.4, BA.5) were expressed from human embryonic kidney 293

(HEK293) cells, purified, and coupled to the fluorescence-encoded

magnetic beads, as previously reported [7, 13]. Prior to the assay, the

resulting beads were blocked and incubated with the samples

containing NAbs. The binding of Abs to the Spike protein blocks its

interaction to the biotinylated ACE2 receptor that is coupled to streptavidin-phycoerythrin (SA-PE). The inhibition rate (%) was the percentage of the Spike-ACE2 interaction signal in the serum samples with NAbs compared to the control without NAbs.

The sensitive detection of Spike-ACE2 interactions is essential for assessing the presence of NAbs in clinical samples. To address this requirement, we coupled the Spike protein from six SARS-CoV-2 VOCs (D614G, Alpha, Beta, Kappa, Delta, Omicron BA.1) onto fluorescent magnetic beads from Luminex and Shenzhen Wellgrow Technology Co., Ltd. ("Wellgrow"), and then incubated with different concentrations of ACE2. Magnetic beads with the SARS-CoV-2 nucleocapsid (N) protein, rather than the Spike protein, was employed as the negative control. The binding signals were measured using Luminex-200 and Wellgrow flow cytometry. Notably, the fluorescent signal intensity was much higher with the Wellgrow platform than the Luminex platform when ACE2 concentrations ranged from 0.01 µg/mL to 100 ng/mL (Figure 1B and Supplementary Figure 1).

Furthermore, we calculated the sensitivity or the lowest detection limit (LOD) of each method, in which the LOD was equal to the signal of the buffer control plus ten standard deviations (Figure 1C). The data showed that the average LOD of our assay using the Wellgrow platform was 35.89±57.8 [-21.91~93.69]-fold higher than the Luminex

platform for all variants (D614G, Alpha, Beta, Kappa, Delta, Omicron

BA.1). Therefore, we selected the Wellgrow platform as the proteomics

platform for the SARS-CoV-2 bNAb assay in this study.

Mapping Spike-ACE2 interactions of SARS-CoV-2 VOCs

Using our platform, we conducted a systematic investigation of the

interactions between ACE2 and Spike trimer proteins from eleven

SARS-CoV-2 VOCs. This was achieved by incubating a bead array

with different concentrations of ACE2 (Figure 2). The results

demonstrated that the fluorescent signals from the Spike trimer

proteins increased with increasing concentrations of ACE2 (Figure 2A),

indicating the formation of Spike-ACE2 complexes on the beads.

Spike mutations were found to influence the interaction dynamics.

At the maximal concentration of 10 μg/mL ACE2, Alpha and Delta

variants exhibited the highest signals, followed by Beta, BA.4, BA.5,

D614G, Gamma, BA.1, BA.2, and Kappa, with BA.3 showing the

lowest signal. In contrast, the N protein, used as a negative control,

consistently displayed the lowest signal regardless of ACE2

concentration.

To further assess the binding affinity, we calculated the

half-maximal effective concentration (EC50) using the standard curve

for each SARS-CoV-2 variant (Figure 2B). The results showed that

Omicron BA.1 has the highest binding affinity with an EC50 of 0.2913

µg/mL, followed by Beta (0.2913 µg/mL), Delta (0.3415 µg/mL),

Omicron BA.4 (0.3592 µg/mL), Gamma (0.3833 µg/mL), Alpha (0.394

µg/mL), Kappa (0.3983 µg/mL), Omicron BA. 2 (0.4307µg/mL),

Omicron BA. 5(0.4593 µg/mL), D614G (0.5279 µg/mL), and Omicron

BA.3 (1.283 µg/mL). The results are in accordance with surface plasma

resonance data in which BA.1 has the strongest interaction with ACE2

with a dissociation constant (K_D) of 2.10 nM, followed by BA.2 (2.21 nM)

and D614G (5.20 nM) [14]. Similar results were obtained by Mahalingam

et al., who used ELISA to determine the EC50 of ACE2 to Spike

Omicron (0.38 nM), Delta (0.48 nM), and wild type (2.28 nM)[15].

Collectively, our data provide a comprehensive landscape of Spike

trimer-ACE2 interactions for SARS-CoV-2 VOCs, as classified by the

U.S. Centers for Disease Control and Prevention (CDC)

(https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-classifica

tions.html). It should be noted that the Epsilon variant was not included

in this work due to the unavailability of purified Spike trimer protein.

Comparison of SARS-CoV-2 bNAb assay to ELISA and sVNT

assays

To assess the reliability of the SARS-CoV-2 bNAb assay, we compared

the SARS-CoV-2 bNAb assay to an ELISA that was used to detect

anti-Spike IgG antibodies[16]. The results showed a high correlation

between the levels of D614G NAbs detected using our SARS-CoV-2

bNAb assay and the anti-Spike IgG antibodies obtained by the ELISA

[R = 0.89, p-value (p) < 2.2 e-16] in a cohort of 75 individuals (Figure

3A).

Next, we compared the NAb results obtained from the

SARS-CoV-2 bNAb assay to those obtained from the FDA-approved

cPass sVNT test [6, 9]. The data obtained using the SARS-CoV-2 bNAb

assay and cPass sVNT test demonstrated a higher correlation to each

other (R = 0.93, p < 2.2 e-16) compared to the assay using Luminex

technology (R=0.85)[17]. The positive percent agreement (PPA) was

92.7% (80.1%-98.5%) and the negative percent agreement (NPA) was

94.1% (80.3%-99.3%) (Figure 3B). The findings suggest that some of

the anti-Spike IgG antibodies detected by the ELISA may lack

neutralizing activity and therefore were not detected by SARS-CoV-2

bNAb assay[18]. Overall, these results demonstrate the reliability of the

SARS-CoV-2 bNAb assay as an *in vitro* platform for detecting serum

NAbs.

Identification of broadly neutralizing monoclonal Abs against

SARS-CoV-2 variants

To demonstrate the application of SARS-CoV-2 bNAb assay in

identifying monoclonal NAbs for potential treatment purposes, we

tested six anti-Spike antibodies that are available in the laboratory[19]

(Figure 4A). The results revealed that three antibodies (#26, #20, #21)

have neutralizing activity. Antibodies #20 and #21 inhibited ACE2

binding to D614G, Alpha, Beta, Kappa and Delta variants, but were not

effective in inhibiting the ACE2 binding to the Omicron BA.1 variant.

Antibody #26 exhibited the ability to inhibit Spike-ACE2 interactions for

D614G, Alpha, Beta, Kappa,Delta and Omicron BA.1 variants.

Subsequently, the half-maximal inhibitory concentration (IC50)

values were calculated and represented in a heatmap (Figure 4B). The

results showed that antibody #26 possessed broad neutralizing activity

to all tested SARS-CoV-2 variants (Kappa, D614G, Alpha, Delta, Beta,

Omicron BA.1). The IC50 to D614G (0.47 µg/mL) was confirmed with

ELISA (0.35 µg/mL) and pseudovirus neutralizing assay (0.21 µg/mL)

in our previous work[19]. While the IC50 of antibody #26 to the Omicron

variant was ten-fold lower than non-Omicron variants. These findings

underscore the ability of our assay to rapidly screen for monoclonal

NAbs with potential therapeutic applications.

Evaluation of serum NAbs in individuals receiving the third dose

vaccination

We tested the serum NAbs from 56 individuals who received two doses

of the inactivated vaccine (Sinovac-CoronaVac) and boosted with a

third dose with either an inactivated vaccine or recombinant subunit

vaccine (ZF2001) (Table 1)[20]. The inhibition rate (%) was calculated by

deducting the background noise using 147 serum samples collected

prior to the COVID-19 pandemic[21]. The results showed that the third

dose vaccination elicited a strong protective immune response against

the non-Omicron variants with the highest inhibition rate (%) of D614G,

followed by Gamma, Alpha, Delta, and Kappa variants. Unfortunately,

the inhibition rate (%) was much lower in Omicron BA.2 (0.44×), BA.1

(0.43×), BA.3 (0.41×), BA.5 (0.35×), and BA.4 (0.33×) variants,

indicating the resistance of these variants to the Sinovac-CoronaVac

vaccine and the ZF2001 vaccine (Figure 5A).

Furthermore, we compared the inhibition (%) of serum NAbs in

individuals who received either a third dose of inactivated vaccine or

recombinant vaccine; no significant difference was observed (Figure

5B). These findings highlight the immunological resistance of different

SARS-CoV-2 variants to the Sinovac-CoronaVac and ZF2001 vaccines,

and suggest the need for developing a new vaccine that provides

broad protection against SARS-CoV-2 variants.

Discussion

In this work, we developed a high-throughput SARS-CoV-2 bNAb

assay to detect a wide range of NAbs to non-Omicron and Omicron

variants. Compared to the assay using Luminex technology[7, 8], our

SARS-CoV-2 bNAb assay is 35-fold more sensitive, 2.5-fold less costly,

and can be accessible to any laboratory that has a standard flow

cytometer with the 532 nm and 635 nm lasers. Moreover, the

simultaneous detection of NAbs to multiple SARS-CoV-2 variants can

be achieved within a single experiment, and the assay can be

periodically updated to include new variants. The reliability of NAb

detection using our SARS-CoV-2 bNAb assay is demonstrated through

comparisons with ELISA-based IgG serology and the cPass sVNT

assay (Figure 3).

Using this platform, we constructed a comprehensive landscape of

Spike trimer and ACE2 interactions for eleven SARS-CoV-2 VOCs

(Figure 2). The results provide evidence that Omicron BA.1 showed the

strongest binding affinity to the ACE2 receptor [22, 23]. Notably, the

transmission rate of SARS-CoV-2 and its variants is dependent on

numerous factors, including immune resistance, toxicity, etc[24].

Furthermore, our investigation of serum NAbs in vaccinated

individuals showed that the third dose of the inactivated vaccine or

recombinant RBD vaccine resulted in a strong inhibition of Spike-ACE2

interactions to the non-Omicron VOCs (D614G, Alpha, Beta, Gamma,

Kappa). However, the protection was significantly decreased for

Omicron VOCs (BA.2, BA.1, BA.3, BA.5, BA.4) (Figure 5). These

results demonstrate the significance of our proteomics platform in

evaluating the broad protective activity of COVID-19 vaccines, which

can guide the development of COVID-19 vaccines.

It is important to acknowledge some limitations of our study. First,

the *in vitro* detection of NAbs may not represent viral neutralization *in*

vivo, although previously reported evidence has shown a good

correlation between NAbs detected *in vitro* and *vivo*[5-8]. Second, the

relationship between the inhibition levels obtained with the

SARS-CoV-2 bNAb assay and the SARS-CoV-2 remains unclear. Third,

the number of clinical samples employed in this study was limited, and

the assay should be executed in a larger cohort to determine the NAb

levels induced by different vaccines and infection with SARS-CoV-2

variants.

301 **Conclusion**

302 We have successfully developed and validated a high-throughput

303 proteomics platform, enabling the comprehensive evaluation of NAbs

304 against a wide range of SARS-CoV-2 VOCs. This platform offers an

305 efficient, sensitive, and cost-effective approach for detecting broad

306 NAbs within the population, providing an opportunity to guide the

design and evaluation of vaccines with enhanced protective efficacy against evolving SARS-CoV-2 strains. Overall, our work contributes to the ongoing efforts in combating the COVID-19 pandemic and advancing our understanding of immune responses to SARS-CoV-2.

References

1. The, L., The COVID-19 pandemic in 2023: far from over. *Lancet* **2023,** *401* (10371), 79.

2. Khoury, D. S.; Docken, S. S.; Subbarao, K.; Kent, S. J.; Davenport, M. P.; Cromer, D., Predicting the efficacy of variant-modified COVID-19 vaccine boosters. *Nat Med* **2023,** *29* (3), 574-578.

3. Ma, Y.; Deng, J.; Liu, Q.; Du, M.; Liu, M.; Liu, J., Long-Term Consequences of Asymptomatic SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis. *Int J Environ Res Public Health* **2023,** *20* (2).

4. Thaweethai, T.; Jolley, S. E.; Karlson, E. W.; Levitan, E. B.; Levy, B.; McComsey, G. A.; McCorkell, L.; Nadkarni, G. N.; Parthasarathy, S.; Singh, U.; Walker, T. A.; Selvaggi, C. A.; Shinnick, D. J.; Schulte, C. C. M.; Atchley-Challenner, R.; Alba, G. A.; Alicic, R.; Altman, N.; Anglin, K.; Argueta, U.; Ashktorab, H.; Baslet, G.; Bassett, I. V.; Bateman, L.; Bedi, B.; Bhattacharyya, S.; Bind, M. A.; Blomkalns, A. L.; Bonilla, H.; Bush, P. A.; Castro, M.; Chan, J.; Charney, A. W.; Chen, P.; Chibnik, L. B.; Chu, H. Y.; Clifton, R. G.; Costantine, M. M.; Cribbs, S. K.; Davila Nieves, S. I.; Deeks, S. G.; Duven, A.; Emery, I. F.; Erdmann, N.; Erlandson, K. M.; Ernst, K. C.; Farah-Abraham, R.; Farner, C. E.; Feuerriegel, E. M.; Fleurimont, J.; Fonseca, V.; Franko, N.; Gainer, V.; Gander, J. C.; Gardner, E. M.; Geng, L. N.; Gibson, K. S.; Go, M.; Goldman, J. D.; Grebe, H.; Greenway, F. L.; Habli, M.; Hafner, J.; Han, J. E.; Hanson, K. A.; Heath, J.; Hernandez, C.; Hess, R.; Hodder, S. L.; Hoffman, M. K.; Hoover, S. E.; Huang, B.; Hughes, B. L.; Jagannathan, P.; John, J.; Jordan, M. R.; Katz, S. D.; Kaufman, E. S.; Kelly, J. D.; Kelly, S. W.; Kemp, M. M.; Kirwan, J. P.; Klein, J. D.; Knox, K. S.; Krishnan, J. A.; Kumar, A.; Laiyemo, A. O.; Lambert, A. A.; Lanca, M.; Lee-Iannotti, J. K.; Logarbo, B. P.; Longo, M. T.; Luciano, C. A.; Lutrick, K.; Maley, J. H.; Marathe, J. G.; Marconi, V.; Marshall, G. D.; Martin, C. F.; Matusov, Y.; Mehari, A.; Mendez-Figueroa, H.; Mermelstein, R.; Metz, T. D.; Morse, R.; Mosier, J.; Mouchati, C.; Mullington, J.; Murphy, S. N.; Neuman, R. B.; Nikolich, J. Z.; Ofotokun, I.; Ojemakinde, E.; Palatnik, A.; Palomares, K.; Parimon, T.; Parry, S.; Patterson, J. E.; Patterson, T. F.; Patzer, R. E.; Peluso, M. J.; Pemu, P.; Pettker, C. M.; Plunkett, B. A.; Pogreba-Brown, K.; Poppas, A.; Quigley, J. G.; Reddy, U.; Reece, R.; Reeder, H.; Reeves, W. B.; Reiman, E. M.; Rischard, F.; Rosand, J.; Rouse, D. J.; Ruff, A.; Saade, G.; Sandoval, G. J.; Schlater, S. M.; Shepherd, F.; Sherif, Z. A.; Simhan, H.; Singer, N. G.; Skupski, D. W.; Sowles, A.; Sparks, J. A.; Sukhera, F. I.; Taylor, B. S.; Teunis, L.;

Thomas, R. J.; Thorp, J. M.; Thuluvath, P.; Ticotsky, A.; Tita, A. T.; Tuttle, K. R.; Urdaneta, A. E.; Valdivieso, D.; VanWagoner, T. M.; Vasey, A.; Verduzco-Gutierrez, M.; Wallace, Z. S.; Ward, H. D.; Warren, D. E.; Weiner, S. J.; Welch, S.; Whiteheart, S. W.; Wiley, Z.; Wisnivesky, J. P.; Yee, L. M.; Zisis, S.; Horwitz, L. I.; Foulkes, A. S.; Consortium, R., Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection. *JAMA* **2023**.

5. Nie, J.; Li, Q.; Wu, J.; Zhao, C.; Hao, H.; Liu, H.; Zhang, L.; Nie, L.; Qin, H.; Wang, M.; Lu, Q.; Li, X.; Sun, Q.; Liu, J.; Fan, C.; Huang, W.; Xu, M.; Wang, Y., Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay. *Nat Protoc* **2020**, *15* (11), 3699-3715.

6. Tan, C. W.; Chia, W. N.; Qin, X.; Liu, P.; Chen, M. I.; Tiu, C.; Hu, Z.; Chen, V. C.; Young, B. E.; Sia, W. R.; Tan, Y. J.; Foo, R.; Yi, Y.; Lye, D. C.; Anderson, D. E.; Wang, L. F., A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. *Nat Biotechnol* **2020**, *38* (9), 1073-1078.

7. Fenwick, C.; Turelli, P.; Pellaton, C.; Farina, A.; Campos, J.; Raclot, C.; Pojer, F.; Cagno, V.; Nussle, S. G.; D'Acremont, V.; Fehr, J.; Puhan, M.; Pantaleo, G.; Trono, D., A high-throughput cell- and virus-free assay shows reduced neutralization of SARS-CoV-2 variants by COVID-19 convalescent plasma. *Sci Transl Med* **2021**, *13* (605).

8. Lynch, K. L.; Zhou, S.; Kaul, R.; Walker, R.; Wu, A. H., Evaluation of Neutralizing Antibodies against SARS-CoV-2 Variants after Infection and Vaccination Using a Multiplexed Surrogate Virus Neutralization Test. *Clin Chem* **2022**, *68* (5), 702-712.

9. Perkmann, T.; Mucher, P.; Osze, D.; Muller, A.; Perkmann-Nagele, N.; Koller, T.; Radakovics, A.; Flieder, I.; Repl, M.; Marculescu, R.; Wolzt, M.; Wagner, O. F.; Binder, C. J.; Haslacher, H., Comparison of five Anti-SARS-CoV-2 antibody assays across three doses of BNT162b2 reveals insufficient standardization of SARS-CoV-2 serology. *J Clin Virol* **2023**, *158*, 105345.

10. Bal, A.; Pozzetto, B.; Trabaud, M. A.; Escuret, V.; Rabilloud, M.; Langlois-Jacques, C.; Paul, A.; Guibert, N.; D'Aubarede-Frieh, C.; Massardier-Pilonchery, A.; Fabien, N.; Goncalves, D.; Boibieux, A.; Morfin-Sherpa, F.; Pitiot, V.; Gueyffier, F.; Lina, B.; Fassier, J. B.; Trouillet-Assant, S.; Group, C. S. S., Evaluation of High-Throughput SARS-CoV-2 Serological Assays in a Longitudinal Cohort of Patients with Mild COVID-19: Clinical Sensitivity, Specificity, and Association with Virus Neutralization Test. *Clin Chem* **2021**, *67* (5), 742-752.

11. Grant, R.; Sacks, J.; Abraham, P.; Chunsuttiwat, S.; Cohen, C.; Figueroa, J., When to update COVID-19 vaccine composition. *Nature Medicine* **2023**, (29), 776–780.

12. Chao, Z.; Han, Y.; Jiao, Z.; You, Z.; Zhao, J., Prism Design for Spectral Flow Cytometry. *Micromachines (Basel)* **2023**, *14* (2).

13. Yu, X.; Hartmann, M.; Wang, Q.; Poetz, O.; Schneiderhan-Marra, N.; Stoll, D.; Kazmaier, C.; Joos, T. O., microFBI: a microfluidic bead-based immunoassay for multiplexed detection of proteins from a microL sample volume. *PLoS One* **2010**, *5* (10).

14. Wang, Q.; Guo, Y.; Iketani, S.; Nair, M. S.; Li, Z.; Mohri, H.; Wang, M.; Yu, J.; Bowen, A. D.; Chang, J. Y.; Shah, J. G.; Nguyen, N.; Chen, Z.; Meyers, K.; Yin, M. T.; Sobieszczyk, M. E.; Sheng, Z.; Huang, Y.; Liu, L.; Ho, D. D., Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. *Nature* **2022**, *608* (7923),

603-608.

15. Mahalingam, G.; Arjunan, P.; Periyasami, Y.; Dhyani, A. K.; Devaraju, N.;
Rajendiran, V.; Christopher, A. C.; Kt, R. D.; Dhanasingh, I.; Thangavel, S.;
Murugesan, M.; Moorthy, M.; Srivastava, A.; Marepally, S., Correlating the differences in
the receptor binding domain of SARS-CoV-2 spike variants on their interactions with human
ACE2 receptor. *Sci Rep* **2023,** *13* (1), 8743.

16. Zhan, H.; Gao, H.; Liu, Y.; Zhang, X.; Li, H.; Li, X.; Wang, L.; Li, C.; Li, B.;
Wang, Y.; Dai, E.; Li, Y., Booster shot of inactivated SARS-CoV-2 vaccine induces potent
immune responses in people living with HIV. *J Med Virol* **2023,** *95* (1), e28428.

17. Marien, J.; Michiels, J.; Heyndrickx, L.; Nkuba-Ndaye, A.; Ceulemans, A.;
Bartholomeeusen, K.; Madinga, J.; Mbala-Kingebeni, P.; Vanlerberghe, V.;
Ahuka-Mundeke, S.; Wang, L. F.; Arien, K. K., Evaluation of a surrogate virus neutralization
test for high-throughput serosurveillance of SARS-CoV-2. *J Virol Methods* **2021,** *297*, 114228.

18. Chen, Y.; Zhao, X.; Zhou, H.; Zhu, H.; Jiang, S.; Wang, P., Broadly neutralizing
antibodies to SARS-CoV-2 and other human coronaviruses. *Nat Rev Immunol* **2023,** *23* (3),
189-199.

19. Liang, T.; Cheng, M.; Teng, F.; Wang, H.; Deng, Y.; Zhang, J.; Qin, C.; Guo, S.;
Zhao, H.; Yu, X., Proteome-wide epitope mapping identifies a resource of antibodies for
SARS-CoV-2 detection and neutralization. *Signal Transduct Target Ther* **2021,** *6* (1), 166.

20. Zhao, X.; Zhang, R.; Qiao, S.; Wang, X.; Zhang, W.; Ruan, W.; Dai, L.; Han, P.;
Gao, G. F., Omicron SARS-CoV-2 Neutralization from Inactivated and ZF2001 Vaccines. *N Engl*
J Med **2022,** *387* (3), 277-280.

21. Zhang, J.; Teng, F.; Zhang, X.; Wang, H.; Liang, T.; Guo, S.; Yu, X.,
Down-regulation of SARS-CoV-2 neutralizing antibodies in vaccinated smokers. *MedComm*
(2020) **2022,** *3* (3), e166.

22. Yin, W.; Xu, Y.; Xu, P.; Cao, X.; Wu, C.; Gu, C.; He, X.; Wang, X.; Huang, S.;
Yuan, Q.; Wu, K.; Hu, W.; Huang, Z.; Liu, J.; Wang, Z.; Jia, F.; Xia, K.; Liu, P.;
Wang, X.; Song, B.; Zheng, J.; Jiang, H.; Cheng, X.; Jiang, Y.; Deng, S. J.; Xu, H. E.,
Structures of the Omicron spike trimer with ACE2 and an anti-Omicron antibody. *Science*
2022, *375* (6584), 1048-1053.

23. Ma, W.; Fu, H.; Jian, F.; Cao, Y.; Li, M., Immune evasion and ACE2 binding affinity
contribute to SARS-CoV-2 evolution. *Nat Ecol Evol* **2023.**

24. Markov, P. V.; Katzourakis, A.; Stilianakis, N. I., Antigenic evolution will lead to new
SARS-CoV-2 variants with unpredictable severity. *Nat Rev Microbiol* **2022,** *20* (5), 251-252.

25. Zhang, X.; Zheng, M.; Wang, H.; Zhou, H.; Liang, T.; Zhang, J.; Ren, J.; Peng,
H.; Li, S.; Bian, H.; Wei, C.; Yin, S.; He, C.; Han, Y.; Li, M.; Hou, X.; Zhang, J.;
Xie, L.; Lv, J.; Kan, B.; Wang, Y.; Yu, X., Inhibitor screening using microarray identifies
the high capacity of neutralizing antibodies to Spike variants in SARS-CoV-2 infection and
vaccination. *Theranostics* **2022,** *12* (6), 2519-2534.

26. Yang, L.; Yu, Y.; Ma, C.; Wang, H.; Dai, J.; Duan, H.; Fu, Z.; Wu, P.; Wang,
D.; Yu, X., Development of RBC Membrane Antigen Arrays for Validating Blood Grouping
Reagents. *J Proteome Res* **2018,** *17* (9), 3237-3245.

27. Robin, X.; Turck, N.; Hainard, A.; Tiberti, N.; Lisacek, F.; Sanchez, J. C.; Muller,
M., pROC: an open-source package for R and S+ to analyze and compare ROC curves. *BMC*

Bioinformatics **2011,** *12,* 77.

Contributions

X.Z. and D.H. executed the experiments; M.L., X. Z., X.Z., X.X., T. L., and Y. Z. performed the data analysis; H.L. and Y.W. provided the clinical samples. X.Y., Y. L., and B.W. wrote the manuscript.

Acknowledgment

This work was supported by the Beijing Municipal Natural Science Foundation (M21003 and M23010), National Key R&D Program of China(2022YFE0210400, 2021YFA1301604, 2020YFE0202200), State Key Laboratory of Proteomics (SKLP-O202007), Academic leader of high-level public health technical personnel construction project of Beijing Municipal Health Commission (2022-2-014), Guangdong Province Science and Technology Planning Project (2020B1111100006), Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine. (No: ZYYCXTD-C-202204). We also thank Dr. Brianne Petritis for her critical review and editing of this manuscript.

Declaration of Interest Statement

The authors have declared no conflict of interest.

Supplementary materials

457   Supplementary Figure 1

Tables

467   Table 1. Clinical serum samples employed in this study

	3rd dose vaccination cohort （n=56）
Gender	
Male	16(28.6%)
Female	40(71.4%)
Age (years)	
Range	21-70
≤50	50(89.3%) 6(10.7%)
> 50	
Vaccination type	
Recombinant RBD-subunit vaccine (ZF2001)	38(83.9%)
Inactivated vaccine (Sinovac-Coron aVac)	18(16.1%)
Days of serum collection after 3rd dose vaccination	28

Figure legends

Figure 1. Schematic illustration of the high throughput SARS-CoV-2 bNAb assay. (A) Workflow of the SARS-CoV-2 bNAb assay. The beads coupled with SARS-CoV-2 VOC Spike trimer proteins are incubated with NAbs. The NAbs with neutralizing activity will block the Spike interaction with biotinylated ACE2 and SA-PE. The signal intensities of the Spike trimer-ACE2 interaction are inversely proportional to the level of NAbs. (B) Dose relationship curve of Spike-ACE2 interactions using Wellgrow and Luminex platforms. MFI = mean fluorescence intensity. (C) A comparison of the sensitivity to

detect Spike-ACE2 interactions with the Wellgrow and Luminex

platforms.

Figure 2. Spike trimer-ACE2 interactions across different

SARS-CoV-2 VOCs and ACE2 concentrations. (A) Dose relationship

curve of the interactions between ACE2 and six SARS-CoV-2

non-Omicron VOCs and five Omicron VOCs. The x-axis represents the

concentrations of the host ACE2 receptor. The y-axis represents the

median of fluorescent signal intensity (MFI) of the SARS-CoV-2 Spike

trimer-ACE2 interaction. N = nucleocapsid protein, which was used as

a negative control. (B) Distribution of the NAb resistance to

SARS-CoV-2 VOCs. The x-axis represents the SARS-CoV VOCs. The

y-axis represents the EC50 calculated from SARS-CoV-2 VOC

Spike-ACE2 interactions.

Figure 3. Comparison of the SARS-CoV-2 bNAb assay results with

results from ELISA-based IgG serology and sVNT assays. (A)

Correlation analysis of serological IgG detection between the

SARS-CoV-2 bNAb assay and an ELISA-based IgG serology. (B)

Correlation analysis of NAb detection using the SARS-CoV-2 bNAb

assay and the FDA-approved cPass sVNT test. Six anti-Spike

antibodies to SARS-CoV-2 Spike variants were analyzed with all

assays. The inhibition rate (%) was calculated using the signal from

Spike trimer-ACE2 binding with and without serum NAbs. The

concordance of NAb detection using the ELISA and sVNT assays was

calculated as the positive and negative percent agreement (PPA and

NPA, respectively). The blue and red dots represent positive

(neutralizing activity) and negative (non-neutralizing) cases as

determined by the comparative analysis, respectively.

Figure 4. Identification of monoclonal Abs with broad neutralizing

capability. (A) Dose relationship curve demonstrating the ability of the

NAb to inhibit SARS-CoV-2 VOC Spike trimer-ACE2 interactions. The

x-axis represents the concentrations of the NAb. The y-axis represents

the inhibition rate (%) of the NAb. N = nucleocapsid protein, which was

used as a negative control. (B) Heatmap showing the IC50 of NAbs

against different SARS-CoV-2 variants.

Figure 5. Detection of serum NAbs in vaccinated individuals. (A, B)

Boxplot showing the distribution of inhibition rate (%) of serum NAbs

against SARS-CoV VOCs in 56 vaccinated individuals. (B) Comparison

of NAbs produced between groups receiving the inactivated vaccine

(Sinovac-CoronaVac) or recombinant subunit vaccine (ZF2001). The

significance was performed using the Student's *t*-test (p-value < 0.01).

, *, and **** represent a p-value less than 0.01, 0.001, and 0.0001,

respectively.

Materials and methods

Collection of clinical samples

Clinical serum samples were collected from Beijing Ditan Hospital 28

days after the third dose of the COVID-19 vaccine (Table 1). Whole

blood was collected in a vacutainer tube, and the serum was obtained

via centrifugation at 4,000 × g at room temperature for 10 minutes. The

serum was then transferred to a clean tube and stored at -80 °C until

use. This study was approved by the Ethics Committee of Beijing Ditan

Hospital (No.2021-010-01), and an exemption of informed consent was

obtained before sera collection[25].

Preparation of SARS-CoV-2 bNAb reagents

The SARS-CoV-2 bNAb assay was developed in ProteomicsEra

Medical Co., Ltd (Beijing, China). Briefly, 3 µg Spike trimer proteins

(Sino Biological. and ACROBiosystems; Beijing, China) were coupled

to 10^6 beads (Shenzhen Wellgrow Technology Co., Ltd.; Beijing, China)

as previously described [26]. First, the beads were activated with

sulfo-N-hydroxysuccinimide (NHS) (Thermo Scientific, USA) (50

mg/mL)   and   1-Ethyl-3-[3-dimethylaminopropyl]-carbodiimide

hydrochloride (EDC) (Solarbio, Beijing, China) (50 mg/mL) by

incubating at room temperature for 20 minutes.

After washing with 2-(N-morpholino) ethanesulfonic acid (MES)

buffer (50 mM, pH 5.0), the beads were incubated with the purified

Spike trimer proteins for 2.5 hours in MES buffer. After an additional

wash, the beads were blocked with the blocking buffer (PBS pH 7.4 ,

0.05% Tween-20, 1% BSA) and then the coated beads were stored at

2-8 °C with the storage buffer (PBS pH7.4 , 0.05% Tween-20, 0.1%

BSA, 0.05% NaN_3).

Detection of Spike-ACE2 interactions using bead-based assays

The SARS-CoV VOC Spike trimer-coupled beads were incubated with

the biotinylated ACE2 (Sino Biological) at 0, 0.014, 0.041, 0.123, 0.370,

1.111, 3.333, 10 µg/mL for 1 hour in a 96-well plate. After washing three

times with PBST-B (PBS pH7.4 , 0.05% Tween-20, 0.1% BSA) , the

Spike-ACE2 interaction was detected using 2 µg/mL SA-PE (Thermo

Scientific, USA) for 30 minutes at room temperature, and the signal

was read with the EasyCell flow cytometer (Shenzhen Wellgrow

Technology Co., Ltd.) at 200 beads/region.

Detection of monoclonal NAbs using the SARS-CoV-2 bNAb assay

To detect monoclonal NAbs, the SARS-CoV-2 Spike trimer

protein-coupled beads were incubated at different concentrations (0,

0.014, 0.041, 0.123, 0.370, 1.111, 3.333, 10 µg/mL) of anti-RBD

antibodies (#26, #20, #21, #22, #23, #73) for 2 hours at room

temperature. After washing the bead three times with PBST-B, the

beads were incubated with the biotinylated ACE2 (0.5 µg/mL) for 1

hour at room temperature, and the binding of ACE2 to Spike trimer

protein was detected using SA-PE (2 µg/mL) for 30 minutes at room

temperature. Finally, the signal was read with the EasyCell flow

cytometry (Wellgrow Technology Co., Ltd.) at 200 beads/region.

Detection of Serum NAbs using SARS-CoV-2 bNAb assay.

The serum samples were diluted to 1:20 with PBST-B and then

incubated with the Spike trimer protein-coupled beads for 2 hours at

room temperature. After washing twice with PBST-B, the beads were

then incubated with the biotinylated ACE2 (0.5 µg/mL) and 2 µg/mL

SA-PE for 1 hour at room temperature. The signal was read with the

EasyCell flow cytometer (Wellgrow Technology Co., Ltd.) at 200

beads/region.

Data analysis

To compare the inhibition rate (%) of serum NAbs against the D614G

variant and other SARS-CoV-2 variants, the raw inhibition rates of

different variants were first normalized using minimum-maximum

normalization. Statistical analyses were performed using Student's

t-test, with a p-value $\leq$ 0.01 considered as statistically significant.

Correlations between the SARS-CoV-2 bNAb, ELISA-based serology

test, and the cPass sVNT test were determined using Pearson

correlation coefficients. Positive and negative percent agreement (PPA,

NPA) were performed using the positive and negative judgment results

from ELISA-based IgG serology and cPass sVNT tests. Ideal cutoffs

for the SARS-CoV-2 bNAb method that maximized PPA and NPA were

calculated using the Youden Index, which was implemented in the R

package pROC (v 1.18.2) [27]. All data analyses were carried out in R

(v4.2.3) under the R studio (v 19.1.3) environment.

A

B

C

LOD [μg/mL]	D614G	Alpha	Beta	Delta	Kappa	Omicron BA.1	Average
Luminex	0.19	0.12	0.16	0.23	0.14	0.12	0.16
Wellgrow	0.006	0.003	0.005	0.003	0.007	0.008	0.005
Fold change [L/W] (×)	31.67	40	32	76.67	20	15	35.89±57.80 [-21.91～93.69]

PPA (%) (95% CI)	NPA (%) (95% CI)
92.7 (80.1-98.5)	94.1 (80.3-99.3)